Prognosis of non-small-cell lung cancer in patients with idiopathic pulmonary fibrosis

Song Yi Han, Yeon Joo Lee, Jong Sun Park, Young Jae Cho, Ho Il Yoon, Jae Ho Lee, Choon Taek Lee, Jin Haeng Chung, Kyung Won Lee, Sang Hoon Lee

Research output: Contribution to journalArticle

Abstract

The risk of lung cancer is higher in idiopathic pulmonary fibrosis (IPF) because both conditions share common risk factors. However, no standard treatment modality for LC in IPF exists due to rare incidence, poor prognosis, and acute exacerbation (AE) of IPF during treatment. We aimed to determine the efficacy of LC treatments and the prognosis in LC patients with IPF according to the LC stage and GAP (gender [G], age [A], and two physiology variables [P]) stage. From 2003 to 2016, 160 retrospectively enrolled patients were classified according to the LC clinical stage and GAP stage. The average (±standard deviation) patient age was 70.1 ± 8.2 years; the cohort predominantly comprised men (94.4%). In GAP stage I, surgery was significantly associated with better survival outcomes in LC. In contrast, no treatment modality yielded significant clinical improvement in GAP stage II/III. The incidences of AE in IPF and its mortality during treatment were 13.8% and 6.3%, respectively. AE occurred commonly in advanced GAP stage. Active treatment should be considered in GAP stage I. The performance status and LC stage should be considered when deciding about the necessity of surgery for patients in advanced GAP stage.

Original languageEnglish
Article number12561
JournalScientific Reports
Volume9
Issue number1
DOIs
StatePublished - 1 Dec 2019

Fingerprint

Idiopathic Pulmonary Fibrosis
Non-Small Cell Lung Carcinoma
Therapeutics
Incidence
Lung Neoplasms
Survival
Mortality

Cite this

@article{42c30a43f69346389bb7c551162acccb,
title = "Prognosis of non-small-cell lung cancer in patients with idiopathic pulmonary fibrosis",
abstract = "The risk of lung cancer is higher in idiopathic pulmonary fibrosis (IPF) because both conditions share common risk factors. However, no standard treatment modality for LC in IPF exists due to rare incidence, poor prognosis, and acute exacerbation (AE) of IPF during treatment. We aimed to determine the efficacy of LC treatments and the prognosis in LC patients with IPF according to the LC stage and GAP (gender [G], age [A], and two physiology variables [P]) stage. From 2003 to 2016, 160 retrospectively enrolled patients were classified according to the LC clinical stage and GAP stage. The average (±standard deviation) patient age was 70.1 ± 8.2 years; the cohort predominantly comprised men (94.4{\%}). In GAP stage I, surgery was significantly associated with better survival outcomes in LC. In contrast, no treatment modality yielded significant clinical improvement in GAP stage II/III. The incidences of AE in IPF and its mortality during treatment were 13.8{\%} and 6.3{\%}, respectively. AE occurred commonly in advanced GAP stage. Active treatment should be considered in GAP stage I. The performance status and LC stage should be considered when deciding about the necessity of surgery for patients in advanced GAP stage.",
author = "Han, {Song Yi} and Lee, {Yeon Joo} and Park, {Jong Sun} and Cho, {Young Jae} and Yoon, {Ho Il} and Lee, {Jae Ho} and Lee, {Choon Taek} and Chung, {Jin Haeng} and Lee, {Kyung Won} and Lee, {Sang Hoon}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-49026-y",
language = "English",
volume = "9",
journal = "Scientific reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Prognosis of non-small-cell lung cancer in patients with idiopathic pulmonary fibrosis. / Han, Song Yi; Lee, Yeon Joo; Park, Jong Sun; Cho, Young Jae; Yoon, Ho Il; Lee, Jae Ho; Lee, Choon Taek; Chung, Jin Haeng; Lee, Kyung Won; Lee, Sang Hoon.

In: Scientific Reports, Vol. 9, No. 1, 12561, 01.12.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognosis of non-small-cell lung cancer in patients with idiopathic pulmonary fibrosis

AU - Han, Song Yi

AU - Lee, Yeon Joo

AU - Park, Jong Sun

AU - Cho, Young Jae

AU - Yoon, Ho Il

AU - Lee, Jae Ho

AU - Lee, Choon Taek

AU - Chung, Jin Haeng

AU - Lee, Kyung Won

AU - Lee, Sang Hoon

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The risk of lung cancer is higher in idiopathic pulmonary fibrosis (IPF) because both conditions share common risk factors. However, no standard treatment modality for LC in IPF exists due to rare incidence, poor prognosis, and acute exacerbation (AE) of IPF during treatment. We aimed to determine the efficacy of LC treatments and the prognosis in LC patients with IPF according to the LC stage and GAP (gender [G], age [A], and two physiology variables [P]) stage. From 2003 to 2016, 160 retrospectively enrolled patients were classified according to the LC clinical stage and GAP stage. The average (±standard deviation) patient age was 70.1 ± 8.2 years; the cohort predominantly comprised men (94.4%). In GAP stage I, surgery was significantly associated with better survival outcomes in LC. In contrast, no treatment modality yielded significant clinical improvement in GAP stage II/III. The incidences of AE in IPF and its mortality during treatment were 13.8% and 6.3%, respectively. AE occurred commonly in advanced GAP stage. Active treatment should be considered in GAP stage I. The performance status and LC stage should be considered when deciding about the necessity of surgery for patients in advanced GAP stage.

AB - The risk of lung cancer is higher in idiopathic pulmonary fibrosis (IPF) because both conditions share common risk factors. However, no standard treatment modality for LC in IPF exists due to rare incidence, poor prognosis, and acute exacerbation (AE) of IPF during treatment. We aimed to determine the efficacy of LC treatments and the prognosis in LC patients with IPF according to the LC stage and GAP (gender [G], age [A], and two physiology variables [P]) stage. From 2003 to 2016, 160 retrospectively enrolled patients were classified according to the LC clinical stage and GAP stage. The average (±standard deviation) patient age was 70.1 ± 8.2 years; the cohort predominantly comprised men (94.4%). In GAP stage I, surgery was significantly associated with better survival outcomes in LC. In contrast, no treatment modality yielded significant clinical improvement in GAP stage II/III. The incidences of AE in IPF and its mortality during treatment were 13.8% and 6.3%, respectively. AE occurred commonly in advanced GAP stage. Active treatment should be considered in GAP stage I. The performance status and LC stage should be considered when deciding about the necessity of surgery for patients in advanced GAP stage.

UR - http://www.scopus.com/inward/record.url?scp=85071763110&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-49026-y

DO - 10.1038/s41598-019-49026-y

M3 - Article

C2 - 31467375

AN - SCOPUS:85071763110

VL - 9

JO - Scientific reports

JF - Scientific reports

SN - 2045-2322

IS - 1

M1 - 12561

ER -